Intra-Cellular Therapies Submits Supplemental New Drug Application for CAPLYTA
On December 3, 2024, Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for CAPLYTA (lumateperone) for the treatment of Major Depressive Disorder (MDD) as adjunctive therapy to antidepressants. This submission follows positive results from Studies 501 and 502, showcasing CAPLYTA’s robust […]
More Stories
Minerva Academy: Release Date, Plot, Cast, Trailer, and More
Netflix’s latest Italian drama Minerva Academy is currently streaming online on the popular streaming network Netflix. Its original title is...
8 Best Commercial Skylight Companies for US Projects (2026)
Getting commercial daylighting wrong is expensive in a way residential work rarely is. A leaking curb on a house is...
Is Sweet Magnolias Season 6 Renewed? Latest News and Review
Netflix’s romantic drama Sweet Magnolias has finally come to an end. In September 2026, Deadline officially announced that one of...
The Inbetweeners 3: Release Date, Cast, Trailer, and Updates
The Inbetweeners 3 is finally coming back on the popular streaming Network, Netflix. The original four stars of the series,...
7 Essential Components of a Modern Corporate Training Tech Stack
What the seven components need to accomplish Your LMS isn’t obsolete. It may simply need to play one part in...
Climate-ready workplaces in 2026: managing heat, flooding, ice and severe weather
Irish and British workplaces are facing severe weather with increasing frequencies, from heatwares and flash flooding to ice underfoot. Preparing...